Sign in

    Stephanie Piazzolla

    Research Analyst at Bank of America

    Stephanie Piazzola is Vice President, Equity Research at Bank of America, specializing in Medical Technology and devices. She covers companies such as iRhythm Technologies, Beta Bionics Inc, Kestra Medical Technologies, and AngioDynamics Inc, with recent reports indicating a 100% success rate and an average return of over 20% on rated stocks. Piazzola joined Bank of America after previous research experience in healthcare; her current tenure has focused on the medical devices segment, operating out of Charlotte, North Carolina. She holds professional securities credentials essential for sell-side analysts, regularly participates in earnings calls, and is recognized for incisive industry analysis.

    Stephanie Piazzolla's questions to TANDEM DIABETES CARE (TNDM) leadership

    Stephanie Piazzolla's questions to TANDEM DIABETES CARE (TNDM) leadership • Q2 2025

    Question

    Stephanie Piazzolla from Bank of America, on for Travis Steed, asked for more detail on what changed regarding the 'commercial evolution' that contributed to the lowered U.S. guidance.

    Answer

    President & CEO John Sheridan explained that the commercial transformation involves both salesforce expansion and system upgrades. While rep productivity improved quarter-over-quarter, the new systems and sales tools are not yet fully implemented. He stated they are being realistic about the second half, acknowledging they are not where they want to be on implementation and are also being cautious due to a new competitor with a large sales force.

    Ask Fintool Equity Research AI